Founded in 2008, Eiger BioPharmaceuticals is a late-stage biopharmaceutical company focused on developing and commercializing targeted therapies for rare diseases.
GBR is pleased to release its Africa Energy 2025 report, following four months of interviews and research across Sub-Saharan Africa, during which time we met with over 120 companies, including those in the upstream, midstream, and downstream sectors, as well as governments, financiers, and service providers.